Cancellation of shares.

No definition available.

Name:	SNYR_CancellationOfShares
Namespace Prefix:	SNYR_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of sale revenue net.

+ References

No definition available.

+ Details

Name:	SNYR_PercentageOfSaleRevenueNet
Namespace Prefix:	SNYR_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of shares purchasable under warrants.

+ References

No definition available.

+ Details

Name:	SNYR_PercentageOfSharesPurchasableUnderWarrants
Namespace Prefix:	SNYR_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Warrants term.

+ References

No definition available.

+ Details

Name:	SNYR_WarrantsTerm
Namespace Prefix:	SNYR_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_AmortizationOfDebtDiscountPremium
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of amortization expense attributable to debt issuance costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(8))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(8))
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name:	us-gaap_AmortizationOfFinancingCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)-(3)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

+ Details

Name:	us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.

+ References

+ Details

Name:	us-gaap_BusinessAcquisitionsProFormaRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Future cash outflow to pay for purchases of fixed assets that have occurred.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

+ Details

Name:	us-gaap_CapitalExpendituresIncurredButNotYetPaid
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737

+ Details

Name:	us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.

+ References

No definition available.

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

+ Details

Name:	us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031897-161870

+ Details

Name:	us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

+ Details

Name:	us-gaap_DebtInstrumentFaceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Incremental percentage increase (decrease) in the stated rate on a debt instrument.

+ References

No definition available.

+ Details

Name:	us-gaap_DebtInstrumentInterestRateIncreaseDecrease
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

+ Details

Name:	us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

+ Details

Name:	us-gaap_DebtInstrumentMaturityDate
Namespace Prefix:	us-gaap_
Data Type:	xbrli:dateItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.

+ References

+ Details

Name:	us-gaap_DeferredFinanceCostsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of accrued but unpaid interest on deposit liabilities.

+ References

+ Details

Name:	us-gaap_DepositLiabilitiesAccruedInterest
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=82849420&loc=SL20226008-175313

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13495-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13433-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

+ Details

Name:	us-gaap_DerivativeLiabilities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name:	us-gaap_InterestExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

+ References

+ Details

Name:	us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16)(a)(2))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name:	us-gaap_LoansPayable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.

+ References

No definition available.

+ Details

Name:	us-gaap_LongTermDebtFairValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name:	us-gaap_NotesPayable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash outflow associated with the purchase of all investments (debt, security, other) during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.

+ References

No definition available.

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfDebt
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.

+ References

+ Details

Name:	us-gaap_UnamortizedDebtIssuanceExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=SNYR_KnightTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_StockOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=SNYR_JuneTwentySixTwoThousandFifteenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=SNYR_USMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=SNYR_JuneThirtyTwoThousandSixteenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=SNYR_QuarterEndingSeptemberThirtyTwoThousandSaventeenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=SNYR_LoanAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=SNYR_STWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=SNYR_SubscriptionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=SNYR_NovemberTwelveTwoThousnadFifteenLoanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=SNYR_AssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=SNYR_JanuaryTwentyTwoTwoThousandFifteenLoanTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=SNYR_JanuaryTwentyTwoThousandSixteenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=SNYR_JanuaryTwentyTwoThousandSaventeenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=SNYR_SecurityAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=SNYR_KnightTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=SNYR_SecondAmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=SNYR_LTWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=SNYR_KnightWarrantSharesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=SNYR_KnightWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=SNYR_JanuaryTwentyTwoThousandFifteenLoanOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=SNYR_KnightWarrantsOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=SNYR_KnightWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=SNYR_FirstAmendmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_NatureOfExpenseAxis=SNYR_OriginationFeeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_NatureOfExpenseAxis=SNYR_WorkFeeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=SNYR_NeuragenCorpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Notes Payable (Details Narrative) - USD ($)							9 Months Ended	12 Months Ended
Notes Payable (Details Narrative) - USD ($)	Aug. 09, 2017	Dec. 22, 2016	Dec. 22, 2016	Nov. 12, 2015	Jun. 26, 2015	Jan. 22, 2015	Sep. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Amount of loan obligation								$ 9,951,512	$ 7,471,148
Recognized amortization of deferred financing costs								223,191	215,302
Interest expense paid								$ (1,044,277)	$ (1,567,867)
Number of common stock issued shares									125,000
Number of common stock purchase									$ 1,456,492
Unamortized debt issuance costs								393,227	163,549
Amortization of debt discount				$ (2,067,258)					1,620,151
Derivative liability				2,067,258
Knight Therapeutics Inc [Member]
Number of common stock issued shares			7,500,000
Number of common stock purchase			$ 2,000,000
Knight Therapeutics Inc [Member] \| Minimum [Member]
Common stock purchase price per share		$ 0.34	$ 0.34
Knight Therapeutics Inc [Member] \| Maximum [Member]
Common stock purchase price per share		0.49	$ 0.49
Warrant [Member] \| Knight Therapeutics Inc [Member]
Cancellation of shares			8,132,002
Stock Option [Member] \| Knight Therapeutics Inc [Member]
Warrants exercise price		$ 0.25	$ 0.25
Cancellation of shares			1,000,000
June 26, 2015 Security Agreement [Member] \| U.S [Member]
Percentage of sale revenue net					5.00%
June 26, 2015 Security Agreement [Member] \| June 30, 2016 [Member]
Note payable					$ 250,000
June 26, 2015 Security Agreement [Member] \| Quarter Ending September 30, 2015 [Member]
Note payable					700,000
June 26, 2015 Security Agreement [Member] \| Minimum [Member] \| June 30, 2016 [Member]
Note payable					$ 12,500
Loan Agreement [Member] \| ST Warrant [Member]
Common stock purchase price per share										$ 1.00
Subscription Agreement [Member] \| Knight Therapeutics Inc [Member]
Number of common stock issued shares		7,500,000
Number of common stock purchase		$ 2,000,000
Subscription Agreement [Member] \| Knight Therapeutics Inc [Member] \| Minimum [Member]
Common stock purchase price per share		$ 0.34	$ 0.34
Subscription Agreement [Member] \| Knight Therapeutics Inc [Member] \| Maximum [Member]
Common stock purchase price per share		0.49	$ 0.49
Subscription Agreement [Member] \| Warrant [Member] \| Knight Therapeutics Inc [Member]
Cancellation of shares			8,132,002
Subscription Agreement [Member] \| Stock Option [Member] \| Knight Therapeutics Inc [Member]
Common stock purchase price per share		0.25	$ 0.25
Cancellation of shares			1,000,000
Subscription Agreement [Member] \| November 12, 2015 Loan [Member] \| Knight Therapeutics Inc [Member]
Number of common stock issued shares			7,500,000
Number of common stock purchase			$ 2,000,000
Subscription Agreement [Member] \| November 12, 2015 Loan [Member] \| Knight Therapeutics Inc [Member] \| Minimum [Member]
Common stock purchase price per share		0.34	$ 0.34
Subscription Agreement [Member] \| November 12, 2015 Loan [Member] \| Knight Therapeutics Inc [Member] \| Maximum [Member]
Common stock purchase price per share		0.49	$ 0.49
Subscription Agreement [Member] \| November 12, 2015 Loan [Member] \| Warrant [Member] \| Knight Therapeutics Inc [Member]
Cancellation of shares			8,132,002
Subscription Agreement [Member] \| November 12, 2015 Loan [Member] \| Stock Option [Member] \| Knight Therapeutics Inc [Member]
Common stock purchase price per share		$ 0.25	$ 0.25
Cancellation of shares			1,000,000
Asset Purchase Agreement [Member] \| Knight Therapeutics Inc [Member]
Debt instrument interest rate percentage								10.00%
Interest expense paid								$ 41,292	59,358
Total payments of acquire assets								1,200,000
Asset Purchase Agreement [Member] \| Knight Therapeutics Inc [Member] \| U.S [Member]
Percentage of sale revenue net							2.00%
Asset Purchase Agreement [Member] \| Knight Therapeutics Inc [Member] \| Minimum [Member] \| U.S [Member]
Percentage of sale revenue net							5.00%
Asset Purchase Agreement [Member] \| January 22, 2015 Loan Two [Member]
Debt instrument interest rate percentage						0.00%
Note maturity date						Jan. 20, 2017
Amount of loan obligation								0	750,000
Note principal amount						$ 1,500,000
Asset Purchase Agreement [Member] \| January 22, 2015 Loan Two [Member] \| January 20, 2016 [Member]
Note payable						750,000
Asset Purchase Agreement [Member] \| January 22, 2015 Loan Two [Member] \| January 20, 2017 [Member]
Note payable						750,000
Security Agreement [Member] \| June 26, 2015 Security Agreement [Member]
Deferred financing costs								10,486
Recognized amortization of deferred financing costs								2,600	5,243
Interest expense paid								41,292	59,358
Note payable								50,000	300,000
Unamortized debt issuance costs								0
Present value of future payments								282,240	290,947
Knight Therapeutics Inc [Member] \| Loan Agreement [Member]
Loan amount	$ 10,000,000			5,500,000		6,000,000
Expenses associated with loan	$ 100,000			$ 24,000		$ 40,000
Debt instrument interest rate percentage	10.50%			15.00%		15.00%
Convertible equity offering						$ 1,000,000
Change in loan interest rate				13.00%		13.00%
Note maturity date	Aug. 08, 2020			Nov. 11, 2017		Jan. 20, 2017
Revenue						$ 13,000,000
Net income (loss)						$ 2,000,000
Amount of loan obligation								562,500	2,812,500
Common stock purchase price per share				$ 0.49
Percentage of shares purchasable under warrants				6.50%
Deferred financing costs								289,045
Recognized amortization of deferred financing costs								56,605	92,976
Interest expense paid								293,238	625,359
Accrued interest expense								0	0
Warrants term				10 years
Derivative liability								4,547,243
Credit facility maximum borrowing amount	$ 20,000,000
Knight Therapeutics Inc [Member] \| Loan Agreement [Member] \| Second Amendment [Member]
Deferred financing costs								452,869
Recognized amortization of deferred financing costs								62,898
Interest expense paid								412,417
Note payable								9,500,000
Accrued interest expense								147,000
Unamortized debt issuance costs								389,970
Knight Therapeutics Inc [Member] \| Loan Agreement [Member] \| ST Warrant [Member]
Number of warrants to purchase common stock						4,595,187
Warrants exercise price						$ 1.00
Beneficial conversion feature of warrants						$ 1,952,953
Knight Therapeutics Inc [Member] \| Loan Agreement [Member] \| LT Warrant [Member]
Number of warrants to purchase common stock						3,584,759
Warrants exercise price						$ 0.34
Common stock purchase price per share						$ 1.00
Percentage of shares purchasable under warrants						25.00%
Beneficial conversion feature of warrants						$ 1,462,560
Knight Therapeutics Inc [Member] \| Loan Agreement [Member] \| Knight Warrant Shares [Member]
Number of warrants to purchase common stock				5,550,625
Amortization of debt discount				$ 2,553,287
Knight Therapeutics Inc [Member] \| Loan Agreement [Member] \| Knight Warrant Shares [Member] \| Maximum [Member]
Number of warrants to purchase common stock				4,547,243
Amortization of debt discount				$ 2,067,258
Knight Therapeutics Inc [Member] \| Loan Agreement [Member] \| January 22, 2015 Loan One [Member]
Debt instrument interest rate percentage						5.00%
Amount of loan obligation						$ 300,000
Aggregate consideration to be paid						100,000
Capital expenditures						100,000
Knight Therapeutics Inc [Member] \| Loan Agreement [Member] \| Knight Warrants One [Member]
Deferred financing costs								3,257
Knight Therapeutics Inc [Member] \| Loan Agreement [Member] \| Knight Warrants [Member]
Recognized amortization of deferred financing costs								101,088	117,083
Interest expense paid								252,515	767,904
Note payable									3,781,250
Accrued interest expense									$ 31,079
Knight Therapeutics Inc [Member] \| Loan Agreement [Member] \| Knight Warrants [Member] \| First Amendment [Member]
Deferred financing costs								233,847
Note payable								0
Accrued interest expense								0
Unamortized debt issuance costs								$ 0
Knight Therapeutics Inc [Member] \| Loan Agreement [Member] \| Origination Fee [Member]
Expenses associated with loan	200,000			110,000		120,000
Knight Therapeutics Inc [Member] \| Loan Agreement [Member] \| Work Fee [Member]
Expenses associated with loan	$ 100,000			$ 55,000		$ 60,000
Neuragen Corp [Member] \| June 26, 2015 Security Agreement [Member]
Debt instrument interest rate percentage					0.00%
Note principal amount					$ 950,000
Total payments of acquire assets					$ 1,200,000
Neuragen Corp [Member] \| June 26, 2015 Security Agreement [Member] \| U.S [Member]
Percentage of sale revenue net					2.00%